European Commission Approves Talzenna to Treat Some Breast Cancers

European Commission Approves Talzenna to Treat Some Breast Cancers
The European Commission (EC) has approved Pfizer's Talzenna (talazoparib) for the treatment of patients with advanced forms of HER2-negative breast cancer with BRCA mutations who have been treated with chemotherapy — before or after surgery, with an anthracycline and/or a taxane — or were not eligible to receive chemotherapy with these agents. Patients with hormone receptor-positive tumors who have received or were not eligible to be treated with endocrine-based therapy may also be eligible for treatment with Talzenna. Talzenna is an inhibitor of the poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair and in the control of programmed cell death. By blocking the activity of PARP, Talzenna prevents cancer cells from repairing their DNA, eventually eliminating them. Last year, the U.S. Food and Drug Administration (FDA) had already approved Talzenna for the treatment of patients with inherited BRCA-mutated, HER2-negative, locally advanced or metastatic breast cancer. The new approval was largely based on findings from the open-label, randomized E
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.